<DOC>
	<DOCNO>NCT02672839</DOCNO>
	<brief_summary>The purpose study compare relative oral bioavailability capsule formulation LGD-6972 solution formulation LGD-6972 .</brief_summary>
	<brief_title>A Comparison Study Bioavailability Capsule Formulation LGD-6972 Oral Solution Formulation</brief_title>
	<detailed_description>This single center , randomize , open-label , single dose study conduct 2-way crossover design . A total 8 subject enrol study . The duration participation subject approximately 36 day , include Screening Period 30 day . Each treatment period , subject admit study site Day -1 observe morning Day 3 ( 48-hour post-dose assessment ) . Over 2 treatment period , subject receive follow treatment single dose orally , fast condition , per randomization ( 4 subject per treatment treatment period : Treatment A - 15 mg LGD-6972 capsule Treatment B - 15 mg LGD-6972 solution Serial blood sample collect 48 hour follow dose determine concentration LGD 6972 plasma . Safety assessment also occur time . Subjects discharge study site 48 hour assessment return study site Days 4 , 7 , 14 follow procedure . Subjects return study site second treatment period additional 7 day . Subjects discharge study return study site Day 14 second treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Healthy , adult man woman , 21 65 year age . If subject woman , must surgically sterile ( hysterectomy bilateral oophorectomy bilateral tubal ligation ) , naturally post menopausal least 12 month follicle stimulate hormone ( FSH ) level postmenopausal range ( take hormone replacement therapy ) consider enrollment 2 . Willing able provide write informed consent 3 . Not diabetic fast blood glucose 70 105 mg/dL , inclusive 4 . In good health significant concomitant pathology base medical history , physical examination , ECG , routine laboratory test ( chemistry , hematology , lipid profile , urinalysis ) , vital sign 5 . Has body mass index ( BMI ) 18.5 kg/m2 30 kg/m2 , inclusive , must weigh 45 kg 6 . Male subject must either vasectomy agree female partner use 2 acceptable form contraception , one must condom , 30 day last dose study drug . Other acceptable form contraception include hormonal contraceptive , intrauterine device , Depo Provera® , Norplant® System Implants , bilateral tubal ligation , bilateral oophorectomy , hysterectomy , contraceptive sponge , foam , jelly . 1 . History drug and/or alcohol abuse within 2 year prior screen 2 . Unwilling comply tobacco , nicotine , alcohol , caffeine restriction outline protocol 3 . Unwilling comply restriction strenuous exercise specify protocol 4 . Has history clinically significant cardiovascular , pulmonary , renal , endocrine , hepatic , neurologic , psychiatric , immunologic , hematologic , gastrointestinal ( include pancreatitis ) , metabolic disease require medical treatment medical problem pose increase risk study may compromise integrity study data 5 . Has liver transaminase level ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] ) 10 % upper limit normal ( ULN ) , creatine kinase ( CK ) level 2 × ULN screen admission site ( Day 1 ) . Abnormal value screen may retested 6 . Has serum triglyceride level 400 mg/dL screening . If triglyceride level 400 mg/dL 500 mg/dL , one retest permit 7 . Recent history uncontrolled high blood pressure systolic blood pressure 90 mmHg 140 mmHg diastolic blood pressure 50 mmHg 90 mmHg screening . One retests blood pressure within reasonable period time permissible discretion Investigator 8 . Is take prescription nonprescription drug outline protocol 9 . Has positive screening hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , and/or human immunodeficiency virus ( HIV ) 10 . Woman childbearing potential 11 . Lactating positive pregnancy test 12 . Has donate 450 mL blood within 56 day admission investigational site donate blood product within 30 day admission .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>